Biotage acquires ATDBio for $62M

By The Science Advisory Board staff writers

October 20, 2021 -- Biotage acquired the U.K.-based privately held company ATDBio for $62 million (45 million pounds).

The acquisition adds DNA and RNA oligonucleotide synthesis and purification platforms to Biotage's portfolio. The platforms are used for drug discovery, molecular diagnostics, nucleic acid-based therapeutics, and new generation DNA and RNA sequencing technologies.

This deal is expected to expand and strengthen Biotage as a leading life science tool and impact technology service provider.

If you like this content, please share it with a colleague!